The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by ACELYRIN, INC. of its common stock for up to an aggregate amount of approximately $150 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “SLRN.”

ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring and accelerating the development and commercialization of transformative medicines.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Dana Lueck-Mammen and Hannah R. Carter. Partner David R. Bauer and associates Adrian Rabin, Shreya R. Kundur and Nazli Ungan provided intellectual property advice. Counsel Christopher A. Baratta and associate Kelsey Nelson provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post